Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| LVLU | Lulu's Fashion Lounge | $12.15 | $5.38 | 79.47% | 22.8M | $19M | $2.98$15.90 |
| BDSX | Biodesix | $8.08 | $2.62 | 47.98% | 75.4M | $43M | $3.44$26.00 |
| SDOT | Sadot Group | $3.71 | $1.17 | 46.06% | 6.4M | $3.9M | $1.17$37.10 |
| OSS | One Stop Systems | $10.45 | $2.38 | 29.49% | 8M | $198M | $1.85$10.72 |
| BIOA | BioAge Labs | $17.85 | $3.82 | 27.23% | 1.9M | $503M | $2.88$17.90 |
| DAWN | Day One Biopharmaceuticals | $11.33 | $2.39 | 26.73% | 8M | $918M | $5.64$13.53 |
| SOGP | Sound Group | $14.79 | $3.09 | 26.41% | 2.5M | $39M | $1.12$35.04 |
| CIGL | Concorde International Group | $2.20 | $0.44 | 24.78% | 1M | $48M | $1.40$31.06 |
| FBRX | Forte Biosciences | $29.66 | $5.78 | 24.20% | 423.4K | $299M | $4.90$31.27 |
| CRWG | Themes ETF Trust - Leverage Shares 2x Long Crwv Daily ETF | $4.17 | $0.81 | 24.11% | 30M | - | $2.42$19.63 |
Related Articles
Featured Article
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
James Brumley|Nov 5, 2025
The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
Prosper Junior Bakiny|Oct 29, 2025
This stock has caught fire after some recent events, but how long will that last?
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
Cory Renauer|Oct 26, 2025
The clinical-stage biotech is working on a new type of weight management drug.
Advertisement
A Motley Fool Potluck of Financial News and Insight
Motley Fool Staff|Dec 3, 2024
It's Motley Fool Money's annual Thanksgiving financial meal. We're serving up humble pie, talking about the topics we're skipping this year at the dinner table, and answering questions you've sent our way.
Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock
Adam Spatacco|Oct 12, 2024
BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.
3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October
Alex Carchidi|Oct 5, 2024
There's a chance that its lead candidate could become one of the top drugs ever.
This IPO Biotech Stock Could Be the Next Eli Lilly
Alex Carchidi|Oct 3, 2024
BioAge has its eyes on a handful of truly gargantuan markets.
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
George Budwell, PhD|Jan 16, 2024
Analysts have high hopes for these three innovation companies in 2024.
Is Beam Therapeutics Stock a Buy Now?
Alex Carchidi|Nov 18, 2023
It has plenty of money, but it'll be facing plenty of competition, too.
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
Alex Carchidi|Oct 31, 2023
Some of the strategic shifts proposed by management are for the better.
